PCMD researcher receives Alzheimer's Association grant to study dementia

NewsGuard 100/100 Score

Dr. David Llewellyn from the Peninsula College of Medicine and Dentistry is the only UK researcher to receive the New Investigator Research Grant from the Alzheimer's Association this year

The US-based Alzheimer's Association has awarded Dr. David Llewellyn of Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, a prestigious two-year $100,000 New Investigator Research Grant to further his dementia research. New Investigator awards are made following international peer review among applicants who are the most promising researchers who have earned their doctoral degrees within the last 10 years.

Dr. Llewellyn is the only researcher in the UK to receive an award from the Alzheimer's Association in 2011.

Dr. Llewellyn's goal is to investigate how low vitamin D levels may increase the risk of dementia and neuroimaging abnormalities, such as brain shrinkage in the US Cardiovascular Health Study. Named collaborators on this international project are Professor David Melzer (PCMD), Professor Kenneth Langa (University of Michigan), Dr Paulo Chaves (Johns Hopkins University) and Dr Bryan Kestenbaum (University of Washington). Support from the Alzheimer's Association will provide funding for a post-doctoral researcher to join Dr. Llewellyn to investigate vitamin D's potential as a biomarker and therapeutic target.

"It is an honour to receive this Alzheimer's Association award - not only for myself but also for the wider Epidemiology and Public Health group at PCMD and our transatlantic collaborators," Dr. Llewellyn said. "Support from the Alzheimer's Association and other funders is vital to accelerate the pace of discovery that we are able to achieve and lay the foundations for our future research programme."

He added: "Unfortunately, the underlying causes of dementia are still largely unknown and current options for prevention and treatment are limited. However, the high proportion of vitamin D deficiency seen in people with cognitive impairment and dementia may provide us with an important clue. Few foods contain vitamin D, synthesis from sunlight is not possible for much of the year at northern latitudes, and skin becomes less efficient at producing vitamin D with age. Given the coming dementia epidemic, we need to investigate new therapeutic strategies such as vitamin D supplementation as a matter of urgency.".

In 2011, the Alzheimer's Association's International Research Grant Program awarded more than $12.8 million in funding to 78 investigators. Funded projects represent the proposals ranked highest by peer reviewers in an extremely competitive field of 875 applications.

"The Alzheimer's Association is pleased that, through this research grant, Dr. Llewellyn and his team will continue their innovative research, and we look forward to seeing his advances in the fight against Alzheimer's disease," said Maria Carrillo, Ph.D., senior director of medical and scientific relations at the Alzheimer's Association.

Dr. Llewellyn and his collaborators published the first study to identify a link between low vitamin D levels and the onset of new cognitive problems last year in the leading journal Archives of Internal Medicine, which attracted widespread international media attention. Dr. Llewellyn's research is also supported by the UK National Institute for Health Research Peninsula Collaboration for Leadership in Applied Health Research and Care (PenCLAHRC) and grants from the James Tudor Foundation, the Norman Family Charitable Trust, the Peninsula College of Medicine and Dentistry Foundation, the Age Related Diseases and Health Trust, and the Sir Halley Stewart Trust.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Smartphone app shows promise in detecting early signs of frontotemporal dementia